| Literature DB >> 26724730 |
Rita Garamvölgyi1, Judit Dobos2, Anna Sipos2, Sándor Boros2, Eszter Illyés2, Ferenc Baska2, László Kékesi2, István Szabadkai2, Csaba Szántai-Kis2, György Kéri3, László Őrfi4.
Abstract
Melanoma is an aggressive form of skin cancer and it is generally associated with poor prognosis in patients with late-stage disease. Due to the increasing occurrence of melanoma, there is a need for the development of novel therapies. A new series of diarylamide and diarylurea derivatives containing imidazo[1,2-a]pyridine or imidazo[1,2-a]pyrazine scaffold was designed and synthesized to investigate their in vitro efficacy against the A375P human melanoma cell line. We found several compounds expressing submicromolar IC50 values against the A375P cells, from which 15d, 17e, 18c, 18h, 18i demonstrated the highest potencies with IC50 below 0.06 μM.Entities:
Keywords: A375P; Antiproliferative activity; Diarylamide; Diarylurea; Imidazo[1,2-a]pyrazine; Imidazo[1,2-a]pyridine; Melanoma
Mesh:
Substances:
Year: 2015 PMID: 26724730 DOI: 10.1016/j.ejmech.2015.12.001
Source DB: PubMed Journal: Eur J Med Chem ISSN: 0223-5234 Impact factor: 6.514